← Back to Clinical Trials
Recruiting NCT03921047

NCT03921047 Characterization of T-cell Repertoire in Patients With Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03921047
Status Recruiting
Phase
Sponsor University of Southern California
Condition Acute Myeloid Leukemia
Study Type OBSERVATIONAL
Enrollment 250 participants
Start Date 2018-04-12
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Biospecimen CollectionLaboratory Biomarker Analysis

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 250 participants in total. It began in 2018-04-12 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This research trial studies characterization of T-cell repertoire through next-generation sequencing in patients with acute myeloid leukemia undergoing stem cell transplant. Characterizing T-cell repertoire may help to understand if immune system plays a significant role in high risk patients with acute myeloid leukemia.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of AML scheduled to undergo HSCT at University of Southern California (USC) Exclusion Criteria: * Inability to provide consent because of severe mental disorders * Donor unwilling to provide consent

Contact & Investigator

Central Contact

Christine Duran

✉ Duran_C@med.usc.edu

📞 323-865-0371

Principal Investigator

Houda Alachkar, PharmD, PhD

PRINCIPAL INVESTIGATOR

University of Southern California

Frequently Asked Questions

Who can join the NCT03921047 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Myeloid Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03921047 currently recruiting?

Yes, NCT03921047 is actively recruiting participants. Contact the research team at Duran_C@med.usc.edu for enrollment information.

Where is the NCT03921047 trial being conducted?

This trial is being conducted at Los Angeles, United States.

Who is sponsoring the NCT03921047 clinical trial?

NCT03921047 is sponsored by University of Southern California. The principal investigator is Houda Alachkar, PharmD, PhD at University of Southern California. The trial plans to enroll 250 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology